<DOC>
	<DOCNO>NCT02829541</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single oral dos BIIB068 healthy participant . Secondary objective characterize single-oral-dose Pharmacokinetic ( PK ) BIIB068 healthy participant , determine effect food single-oral-dose PK BIIB068 healthy participant examine effect administration proton pump inhibitor ( PPI ) esomeprazole single-dose PK BIIB068 healthy participant .</brief_summary>
	<brief_title>A Phase 1 , Single-Ascending-Dose , Safety , Tolerability , Pharmacokinetic ( PK ) , Pharmacodynamic ( PD ) Study BIIB068 Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Key All male subject must practice highly effective method contraception study willing able continue contraception donate sperm least 1 spermatogenic cycle ( 90 day ) administration last dose study treatment . All female subject childbearing potential must practice highly effective method contraception study willing able continue contraception least 1ovulatory cycle ( 30 day ) last dose study treatment . Must body mass index ( BMI ) 18 32 kg/m2 Must good health determine Investigator , base medical history screening evaluation . Key History clinically significant cardiac , endocrine , gastrointestinal ( GI ) , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal disease , major disease , determine Investigator . History severe allergic anaphylactic reaction , history allergic reaction opinion Investigator likely exacerbate component study treatment . Clinically significant abnormal laboratory test value , determine Investigator , Screening Day1 . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Single Ascending Dose ( SAD ) , Healthy Volunteers</keyword>
</DOC>